Theragnostics, an advanced combination of diagnostic and targeted therapy technology, uses radiopharmaceuticals to seek, find, and eliminate metastatic cancer cells while sparing healthy tissue. It is now available at UT Southwestern for pancreatic, thyroid, and several other cancers.
Men with localized, low- and intermediate-risk prostate cancer are seeking TULSA: an outpatient, alternative to surgery or active surveillance: no incisions, surgery, or radiation required. Learn more.
With brachytherapy, tiny implements deliver radiation directly to a tumor. And the list of cancers for which it is effective is expanding. Learn more about how UT Southwestern is leading the way in brachytherapy in Texas.
Severe back pain might be a sign of a more serious underlying medical emergency. In this week’s MedBlog, two spine experts discuss five symptoms that should indicate seeing a doctor right away. Read more.
Men with prostate cancer and their partners often are reluctant to talk about sexual health after treatment, but it’s a natural concern. Learn about a treatment called SAbR that can preserve sexual potency and about a clinical trial that we hope will make it even safer.
Men with prostate cancer want to know the future: Will my cancer get worse? Do I need surgery? Genomic testing can help us make educated recommendations, but it’s far from perfect. Claus Roehrborn, M.D., explains why genomic testing isn’t a “crystal ball” for predicting prostate cancer risk.
Dr. Claus Roehrborn and colleagues in Urology and Radiology are using a new, targeted biopsy method for prostate cancer that’s more effective than standard biopsies – and they’ve just reached a significant milestone.